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Effect of urolithins A and B on ectopic endometrial
growth in a murine model of endometriosis
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Analía Gabriela Ricci,a Mariela Andrea Bilotasa and Rosa Inés Barañaoa
Endometriosis is an often painful disease in reproductive-aged women, in which endometrial-like tissue
grows outside the uterine cavity. Since the limited current therapeutic alternatives fail in alleviating the
symptoms and based on our previous research in in vitro models using the same compounds as the ones
used in the present study, we aimed to evaluate the effects of urolithins A (UA) and B (UB) on the growth
and survival of endometriotic-like lesions in a murine model of endometriosis. Female BALB/C mice were
surgically induced with endometriosis and treated with 2.5 mg kg−1 day−1 intraperitoneal UA or UB. The
mice were monitored daily and weighed and the estrous stage was determined. After 28 days of treat-
ment, lesions were counted, measured, excised, and fixed. Both urolithins proved not to affect the estrous
cycle or body weight of the mice. UA completely prevented endometriotic-like lesions, while UB dimin-
ished the implant volume (p < 0.05). Treatment also reduced epithelial and stromal cell proliferation
within the implants (p < 0.001 and p < 0.01, respectively) and apoptosis was enhanced (p < 0.05 and p <
0.01, respectively). These results are promising and reveal that urolithins A and B, separately, have a ben-
eficial effect on the overall endometriotic growth without affecting the body weight or estrous cycle.
1. Introduction
Endometriosis is a benign gynaecological disease defined by
the presence of endometrial tissue outside the uterine cavity
that commonly arises during the reproductive age of
women.1,2 As the disease is estrogen-dependent,3–6 treatment
options for endometriosis are combined oral contraceptives
and progestins,7,8 creating a state of iatrogenic menopause or
pseudo-pregnancy.9 The classical treatments have important
disadvantages, including suppression of reproductive func-
tion, a high rate of recurrence, and other adverse effects that
limit their long-term use.7,10–12 Subsequently, endometriosis
has a substantial effect on the quality of life of patients,13–16
with negative consequences on daily life activities, sexual func-
tion and personal relationships.
Over the years, natural compounds have become a valuable
resource due to their potential use in the development of treat-
ments for various pathologies.17–21 Recent reports have
demonstrated by in vivo and in vitro studies that polyphenols,
flavonoids and other antioxidants are able to inhibit prolifer-
ation, induce apoptosis and cause cytotoxicity in cancer cells
without affecting healthy cells.22–24 This is of particular inter-
est because although endometriosis is a benign disorder, it
shares important characteristics with cancer,25 like the ability
of endometriotic cells to invade distant tissues, low levels of
apoptosis, and high rates of cell proliferation. Urolithins are a
subfamily of metabolites generated by the human intestinal
microbiota32,33 from ellagitannins and EA, which are polyphe-
nols mainly found in fruits such as strawberries, raspberries,
blueberries, blackberries, walnuts, pomegranates and musca-
dine grapes.34,35 They are dibenzopyran-6-one derivatives with
different hydroxyl substitutions, produced through the loss of
one of the two lactones present in EA and by successive
removal of hydroxyls.32 The major end products of these meta-
bolic reactions are 3,8-dihydroxy-6H-dibenzo[b,d]-pyran-6-one
known as UA and its mono-hydroxy analogue known as UB.36
In previous in vitro studies, it has been demonstrated that they
have anti-inflammatory, anticancer, antioxidant, antimicrobial
and antiestrogenic effects.37,38 Moreover, in our most recent
work we demonstrated for the first time the anti-proliferative,
anti-migratory, anti-invasive and pro-apoptotic effects of UA
and UB in a variety of in vitro models of endometriosis.39
In this sense, several studies have shown that ellagic acid
(EA) and especially its metabolites, the urolithins, exert a
wide range of beneficial health effects including anti-oxidant,
anti-inflammatory, anti-estrogenic and anti-carcinogenic
effects.26–31 However, until now there has been no evidence of
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their systemic effect on endometriotic-like lesion development
in an in vivo model of endometriosis.
Due to the questioned efficacy of the current therapeutics,40
and based on previous studies performed by our research
group,39,41–43 we focused our search for alternative therapies
towards natural compounds. The aim of our study was to
evaluate the effects of urolithins A (UA) and B (UB) in vivo on
the growth and survival of endometriotic lesions in experi-
mental endometriosis in a BALB/c mouse model.
2. Experimental methods
2.1. Animals
In this study, 40 2-month-old female BALB/c mice were used.
All procedures were performed according to the NIH guide-
lines for the care and use of laboratory animals and approved
by the Instituto de Biología y Medicina Experimental (IBYME)
Ethics and Research Committee (CE 025-2/2012) and IBYME
Institutional Commission for the Care and Use of Laboratory
Animals (CICUAL: 031/2016), Buenos Aires, Argentina. A total
of 5 animals died or had to be sacrificed between 2 and 3 days
after surgery because they did not fully recover from the
intervention.
2.2. Surgical induction of endometriosis
Endometriotic-like lesions were induced through transplan-
tation of one of the uterine horns to the bowel mesothelium as
previously described.44 Briefly, animals were deeply anesthe-
tized with an intraperitoneal injection of ketamine (120 mg
kg−1) and xylazine (10 mg kg−1). Afterwards, mice underwent
laparotomy by a mid-ventral incision to expose the uterus and
the intestine. The right uterine horn of each animal was
removed, opened longitudinally, and then cut into 4 mm2
pieces. Three equal pieces of tissue of identical size and
characteristics were then sutured onto the mesothelium layer
with a single 6–0 nylon suture (Supralon, Ethicon, Somerville,
NJ, USA) with the endometrial tissue facing the serosa. Finally,
the abdomen was then closed with a 5–0 nylon suture.
Because surgery itself can have effects on the immune
system, we also included a group of sham animals. These
animals underwent the same surgical procedure, in which the
uterine horn was removed, but no tissue was sutured.
2.3. Experimental design
14 days after surgery, animals with induced endometriosis
were randomly assigned into three different treatment groups:
control (1% DMSO in PBS), UA (Santa Cruz, 2.5 mg kg−1 in
PBS with 1% DMSO) and UB (Santa Cruz, 2.5 mg kg−1 in PBS
with 1% DMSO). Sham animals received the vehicle (PBS with
1% DMSO). All treatments were administered daily by intraper-
itoneal injection, for 28 consecutive days and started on post-
operative day 14, a time point at which the endometriotic
lesions are considered to be already developed.45,46 Mice were
monitored daily.
Urolithin levels can reach up to micromolar concentrations
in human serum depending on the microbiota
composition,36,47,48 which leads to a large inter-individual
variability in urolithin levels.33,49,50 Therefore, in order to
bypass the intrinsic individual variation in microbiota,51 we
injected UA and UB directly into the peritoneal cavity, in agree-
ment with the doses and administration route used in pre-
vious in vivo model studies.51–53
The endometriosis induction/treatment protocol was
applied as follows:
Day 0: arrival of the animals to the in-house animal facility.
Day 7: endometriosis induction surgery.
Day 14: treatments began to be administered daily.
Day 42: end of the experiment/sacrifice.
2.4. Evaluation of the well-being of mice
Mice were carefully observed to detect any changes in their
grooming behavior, activity levels and food consumption from
post-surgical day 1 up to the day of sacrifice. They were
weighed twice a week starting 14 days after the induction
surgery.
2.5. Evaluation of the estrous cycle
To assess the effect of these therapies on the estrous cycle, all
groups were sampled once a day by the vaginal smear
method54 during the last 16 days of treatment.
Vaginal samples were collected between 8 and 9 a.m., and
40 µl of physiological solution was inserted into the
vaginal cavity at room temperature, withdrawn, and smeared
on a microscope slide. Estrous cycle stages were
determined according to the type, number, and morphology of
the cells in the smear. Diestrus index was calculated using the
formula:55
Diestrus index ¼ number of dayswith a clear diestrus smear
total duration of cycleddays
 100
Estrous cyclicity was evaluated from three aspects: (1) the
number of cycles observed in 16 consecutive days, counting
both complete and incomplete cycles; (2) the cycle length
which was calculated by counting the days between two succes-
sive estrous stages with both proestrus and diestrus stages
occurring in between; and (3) the number of days or time
spent in each stage.
2.6. Evaluation of endometriotic-like lesions
After 28 days of treatment, animals were sacrificed by cervical
dislocation. The abdomen was opened by a ventral midline
incision. Implantation sites were localized by the presence of a
lesion or a suture alone. Lesions were counted and measured
in two perpendicular diameters (d, D) using a calliper.
The system of classification of the growth of the lesions was
used in accordance with the study by Quereda et al.56 with
modifications: Grade 0 (the lesion had disappeared, or if it
was visible it never became a cyst), Grade 1 (the lesion formed
a vesicle whose major diameter was <2 mm or, if larger, it was
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solid), Grade 2 (the lesion formed a cyst with fluid, and its
major diameter was ≥2 mm, but <4 mm), and Grade 3 (the dia-
meter of the vesicle was ≥4 mm).
Lesion volumes were determined using the following
formula (where r and R are the radii, r < R):57
V ¼ 4
3
 π r2  R
Then lesions were excised, fixed, embedded in paraffin, and
cut into 5 µm serial sections. Several sections from each speci-
men were stained with hematoxylin–eosin and examined
microscopically for the presence of histological hallmarks of
endometriosis.
2.7. Immunohistochemistry for proliferating cell nuclear
antigen
Serial sections of endometriotic-like lesions were subjected to
standard immunohistochemistry procedures for proliferating
cell nuclear antigen (PCNA) as described previously.58 Briefly,
the sections were incubated with rabbit anti-mouse PCNA poly-
clonal antibody (1 : 800, FL-261, Santa Cruz Biotechnology,
Santa Cruz, USA) and the corresponding secondary biotiny-
lated antibody (1 : 200, rabbit biotinylated anti IgG antibody,
Sigma-Aldrich). They were then incubated with a streptavidin-
peroxidase conjugate (Dako) and exposed to diaminobenzidine
(DAB, Dako) as the peroxidase substrate. Finally, the sections
were counterstained with Gill’s hematoxylin. The presence of
brown nuclear reactivity indicated PCNA-positive cells.
Negative controls were carried out, replacing the primary anti-
body with a rabbit immunoglobulin G isotype antibody
(1 : 800, Roche). The number of PCNA immunopositive cells
was established using a standard light microscope at 400×
magnification. At least 300 epithelial and stromal cells were
counted from representative fields, considering all lesions.
The percentage of PCNA positive cells was established per
mouse, blinded to the treatment conditions, and the mean
value per group was calculated.
2.8. TUNEL assay
For apoptosis quantification, the sections were processed for
in situ immunolocalization of nuclei exhibiting DNA fragmen-
tation by the terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP nick-end labeling (TUNEL) technique, using
the In Situ Cell Death Detection Kit, POD (Roche). As a negative
control, the tissue samples were subjected to treatment
without TdT. At least 300 epithelial and stromal cells were
counted, and the percentage of TUNEL positive cells was calcu-
lated per mouse, blinded to the treatment conditions, and the
mean value per group was calculated.
2.9. Statistical analysis
Statistical analyses were performed using GraphPad PRISM
software 6.0 (GraphPad Software Inc.). Statistical comparisons
between groups were performed using parametric one-way ana-
lysis of variance (ANOVA) followed by Tukey’s multiple com-
parison test, or nonparametric one-way ANOVA (Kruskal–
Wallis) followed by Dunn’s multiple comparison test.
Student’s t-test or the nonparametric Mann–Whitney test was
used for statistical comparisons between two groups.
Results were expressed as mean ± standard error (SEM); p <
0.05 was considered statistically significant.
3. Results
3.1. Effect of UA and UB on the well-being of mice
Given the chronic nature of this disease, one of the challenges
is to find a treatment with few side effects.11 Therefore, in our
study, the mice were monitored daily to examine whether the
treatment with urolithins leads to variations in weight. All
mice gained weight during the post-surgical period, as
expected in young mice. Urolithin-injected mice gained a
similar weight per week compared to the control or even sham
mice (Fig. 1A). The average body weight of UA/UB-treated mice
at 28 days after injection was also not different from those of
the controls. These results revealed that neither the disease
nor the treatment generated statistically significant modifi-
cations in the body weight (Fig. 1B) or the food intake.
Besides, the behavior and the activity levels of the animals
were also unchanged.
3.2. Effect of UA and UB on the estrous cycle
A further important aspect to be evaluated is the potential effect
on the estrous cycle since signs such as persistent diestrus, and
non-cyclic and lengthy estrus cycles are considered indicators of
the compound’s toxicity.55 Therefore, we next examined the
estrous cycle of all animals during the last 16 days of treatment.
The normal estrous cycle has a characteristic periodicity. This
examination showed that the estrous cycle pattern of all groups
remains regular (Fig. 1C). When analyzing the results of all
mice involved in this study, no significant differences were
observed either in the number of cycles or in their duration
between the different groups (Fig. 1D and F).
To quantify the time course of the estrous cycle, we
graphed the data per group as days spent in each stage of the
cycle. In all cases, a regular estrous cycle pattern was observed.
Even though some variations can be observed between groups,
the mean time spent in each stage showed no statistically sig-
nificant difference (Fig. 1F). The same is true even for diestrus
indexes (sham: 48.64%, control: 33.06%, UA: 39.60%, and UB:
36.83%; p > 0.05 vs. control or sham in all cases).
Overall, these data clearly demonstrated that the treatment
with urolithins does not generate any alterations of the estrous
cycle with respect to the control or the sham group.
3.3. Morphological and histopathological evaluation of the
endometriotic-like lesions
After 28 days of treatment with UA or UB, animals were sacri-
ficed and the abdominal cavity was explored to localize and
measure the developed lesions. The results of this macroscopic
cavity examination revealed that all animals that underwent
the induction surgery had developed lesions or, in their
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absence, the sutured and undeveloped initial implanted tissue
was visualized, confirming the efficiency of the surgical induc-
tion of endometriosis. As expected, no lesion or tissue was
observed in the sham group.
Regarding the grade of lesion growth, the treatments
increased the presence of lesions with growth grade 0, and
decreased the incidence of lesions with growth grade 3
(Table 1). Particularly, lesions with growth grade 0 were more
frequent in the UA group (95.2% vs. 30.4% in the control
group).
Moreover, morphological analyses revealed ovoid-shaped
lesions, while the histopathological evaluation
showed typical endometrial components such as glands and
stroma, confirming successful experimental endometriosis
(Fig. 2A).
3.4. Effect of UA and UB on endometriotic-like lesion growth
Fig. 2 shows the percentage of lesions developed per
animal and their size at the end of the experiment. Both
UA and UB caused a reduction in the percentage of
developed lesions per mouse compared to the control
group (Fig. 2B). UB treated animals developed about 50%
of the surgically induced lesions; while in the
group treated with UA, only one animal developed a single
lesion.
Fig. 1 Weight variations and estrous cyclicity of mice. All mice were weighed twice a week and the mean per week was calculated. (A) Mean weight
gain per week per group. (B) Progression of mouse body weight throughout the treatment. The estrous cycle (P: proestrus, E: estrus and D: diestrus)
of all the animals was evaluated. (C) Representative graphs of one animal per group showing the evolution of the estrous cycle; (D) number of
estrous cycles in 16 days; (E) total duration of the estrous cycle; (F) time spent in each stage of the estrous cycle. Results are expressed as mean ±
SEM. N is expressed in parentheses in the graphs.
Table 1 Grade of lesion growth reported for lesions on each group
Grade of lesion growth
Control UA UB
N (%) N (%) N (%)
Grade 0 7 (30.4) 20 (95.2) 14 (56)
Grade 1 — — —
Grade 2 4 (17.4) — 5 (20)
Grade 3 12 (52.2) 1 (4.8) 6 (24)
Total 23 (100) 21 (100) 25 (100)
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Moreover, treatment with UB caused a statistically signifi-
cant decrease in the end-point volume of developed lesions
compared to the control group (Fig. 2C) (p < 0.05).
3.5. Effect of UB on the cell proliferation of endometriotic-
like lesions
Cell proliferation was evaluated in the histological sections of
developed endometriotic-like lesions by immunolocalization
of PCNA. Cell proliferation in the epithelial fraction (Fig. 3A)
of the lesions was significantly diminished compared to the
control group when animals were treated with UB (UB p <
0.001 versus control); similarly, this treatment significantly
reduced the stromal (Fig. 3B) proliferating cells compared to
the control group (UB p < 0.01 versus control).
Micrographs show representative histological sections of
endometriotic-like lesions (Fig. 3C).
3.6. Effect of UB on cell apoptosis in endometriotic-like lesions
In accordance with the results obtained for cell proliferation, UB
significantly increased the apoptotic index in epithelial and
stromal cells of endometriotic-like lesions (Fig. 3D: UB p < 0.05
versus control for epithelial cells, Fig. 3E: UB p < 0.01 versus
control for stromal cells). Micrographs show representative histo-
logical sections of endometriotic-like lesions (Fig. 3F).
Fig. 2 Endometriotic-like lesion development. After 28 days of treatment, the animals were sacrificed and the peritoneal cavity was examined. (A)
Representative images of endometriotic-like lesions: control and UB groups (the UA image is not shown since only one lesion was found).
Magnification: 400×. (B) Percentage of lesions developed per mouse and (C) volume of lesions developed in each experimental group. Results are
expressed as mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 versus control group. N is expressed in parentheses in the graphs.
Fig. 3 Immuno-histochemical assessment of proliferation and apoptosis on endometriotic-like lesions. After 28 days of treatment, the developed
lesions were removed and fixed. Cell proliferation within the implants was evaluated by immunohistochemistry of PCNA. The percentage of PCNA+
(A) epithelial and (B) stromal cells was quantified. Photomicrographs of PCNA immunostaining are displayed (C). Inset: one section of each slide was
incubated with rabbit IgG isotype antibody as a negative control. Magnification: 400×. Apoptosis within the implants was evaluated by a TUNEL
assay. The percentage of TUNEL+ (D) epithelial and (E) stromal cells was quantified. Photomicrographs of TUNEL immunostaining are displayed (F).
One section of each slide was incubated in the absence of TdT enzyme as a negative control. Magnification: 400×. Results are expressed as mean ±
SEM. **p < 0.01 and ***p < 0.001 with respect to the control group. N is expressed in parentheses in each bar.
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4. Discussion
Current treatment for endometriosis usually includes surgery
and/or prolonged hormonal manipulation, aimed at ameliorat-
ing the symptoms of the disease. As stated by de Ziegler
et al.,59 it is essential that the relative benefits of each thera-
peutic option are weighed and that the main reason for their
choice does not derive from the main activity of the first con-
sulting professional, since it is a complex disease that inter-
twines different symptoms depending on each patient. Even
though great efforts are being taken by researchers to give
better and longer lasting answers to patients, the high recur-
rence rate and the numerous side effects of the medical
treatments7,10–12 are some of the most challenging problems
faced nowadays. This has led investigations to focus on
finding new and more effective alternatives for patients. A
variety of natural compounds found in food and plants, some
specific phytochemicals extracted from them, and multi-com-
ponent herbal preparations are being tested for the treatment
of different diseases such as cancer60 and even
endometriosis.32–34,61 Given that most dietary polyphenols
undergo extensive metabolism by the microbiota of the intes-
tine,62 and taking into account previous results obtained in
our laboratory and earlier promising results obtained in
cancer studies, in the present study we focus on urolithins A
and B as the major active metabolites of EA.32,34
Given the potential impact of endometriosis symptoms on
mental well-being and social functioning,63 the behavioral
evaluation of mice subjected to the endometriosis model is an
interesting aspect to take into account when we evaluate their
well-being. Previously, several behavioral alterations had been
observed in rat endometriosis models resembling human
depression, such as anxiety, anhedonia, apathy, and despair-
like behavior, as well as changes in pain sensitivity.64 In this
sense, our results indicated that there were no differences in
the weight gain per week for the different groups (Fig. 1A).
Moreover, our findings indicate that urolithins did not alter
food consumption, grooming behavior, or activity levels.
Due to the importance of estrogen in this pathology,3 we
decided to evaluate whether the estrous cycle was altered upon
treatment. Evaluation of the estrous cycle in experimental
animals65 is a useful indicator of the integrity of the hypo-
thalamic–pituitary–ovarian axis and the state of functioning of
the female reproductive system, and it can also be used to
investigate the impact of drugs/treatments on reproductive
function. Our results indicated that treatment with both uro-
lithins did not disrupt the reproductive cycle. As previously
stated by Cooper and Goldman,66 vaginal cytology samples
must be collected over at least 14 consecutive days in order to
allow one to identify any cyclicity alterations. Considering this,
in our work we took samples of the animals for 16 consecutive
days. Usually, the estrous cycle length in mice averages 4–5
days, but occasional 6-day cycles may be observed in some
mice.67,68 Consequently, in this study, the cycle length averages
5–6 days (Fig. 1E). Regarding the time spent in each stage,
even though it varies between 6 and 72 h depending on the
stage and individual mouse,68 it has been established that
diestrus is the longest with an average duration of 48–72 h.65
Accordingly, we assessed both the time spent in each stage
and the percentage of days in diestrus (diestrus index) over 16
days and concluded that there were no statistically significant
differences between groups (Fig. 1F). In addition, by histo-
logical analyses we were able to recognize the typical structures
of the ovaries and uterus (data not shown), which led us to
conclude that the treatments do not affect the morphology
and histology of these organs. Overall, our results indicated
that after 28 days of experimentation all the groups displayed
regular estrous cycles (Fig. 1C–F) characterized by a similar
number, length and time spent in each stage. However, more
specific assays are needed to determine the effect of the treat-
ment on the ovarian function.
We then evaluated the effect of UA and UB on endometriotic-
like lesions. In a previous report using the autologous surgery
model, Kizilay et al.69 sacrificed 2 test animals 10 days after
induction surgery and confirmed that the endometriosis model
had been created macroscopically and microscopically. A first
comparison among the groups was made through the grade of
lesion growth (Table 1). Based on the results obtained for the
control group, the development of experimental endometriosis
in our study was satisfactory, since in all the cases at least 1 of
the 3 ectopic tissues implanted was found during the induction
surgery. In particular, 52.2% of the lesions in the control group
belonged to the most advanced grade (grade 3), while almost all
the implants in the UA group (95.2%) were of the lowest develop-
mental grade (grade 0). The results demonstrate that UA treat-
ment leads to the non-development of endometriotic-like
lesions. This classification of the growth of the implants pro-
posed by Quereda et al.56 allows us to do a macroscopic evalu-
ation of the growing degree of self-transplanted tissues and vali-
dates the model.70 Moreover, the hematoxylin–eosin stained sec-
tions of all the lesions confirmed the presence of histological
hallmarks (glands and stroma) of endometriosis (Fig. 2A).
In our study, we also found that both UA and UB were able to
decrease the number of established lesions per mouse (Fig. 2B),
especially UA which undoubtedly completely inhibited endome-
triotic-like lesions. Moreover, UB exerted a statistically significant
reduction of the end-point size of the lesions (Fig. 2C), by dimin-
ishing cell proliferation and increasing apoptosis in stromal and
epithelial cells (Fig. 3), two characteristics that are known to be
dysregulated in the endometriotic lesions and the eutopic endo-
metrium of women with endometriosis.71–73 It is important to
emphasize that the treatments began 14 days after surgery, in
order to evaluate the possible effect on the growth, maintenance
and regression of already established endometriotic-like lesions
rather than just their establishment. This certainly reflects what
actually occurs with patients, who consult a specialist once the
lesions are already established.
In various in vivo and in vitro cancer models, urolithins
have proven to have anti-proliferative, pro-apoptotic and anti-
angiogenic activity and anti-tumor effects.32,38,53,74,75
Moreover, Fu et al.76 demonstrated that UA significantly inhib-
ited the IL-1β-induced inflammatory response by targeting the
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PI3K/Akt/NF-κB signalling pathway in osteoarthritis in vitro
and in vivo models. These findings are promising since recent
results from our laboratory77 confirmed the alteration in the
PI3K/AKT pathway regulation in endometriosis patients and
demonstrated clear differences between the stages of endome-
triosis, emphasizing the importance of this pathway in the
first stage of the disease.
In summary, we were able to demonstrate the effectiveness
of UA and UB in the reduction in the number of endometrio-
tic-like lesions and their size by anti-proliferative and pro-
apoptotic effects, without affecting the body weight or estrous
cycle. Therefore, taking into account that suppression of hor-
monal stimulation is one of the currently prescribed pharma-
cological treatments for endometriosis, our findings suggest
that urolithins could be a safe treatment option because of
their non-interference with cyclicity and support their use as
putative compounds for the treatment of this disease. To the
best of our knowledge, this is the first study to describe the
inhibitory effects of these two compounds in endometriosis
development. A major challenge remains in the identification
of accurate doses without affecting fertility or pregnancy in
reproductive aged endometriosis patients.
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